Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 11/20 | 0.70 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7512313 | 0.83 | SRC (1.00) | SRCAKT1JAK3JAK2JAK1 | |
| SCHEMBL14982762 | 0.81 | SRC (0.72) | SRCEGFRLRRK2JAK3JAK2 | |
| SCHEMBL29942401 | 0.78 | SRC (0.48) | SRCAKT1NTRK1ADRA1A | |
| SCHEMBL14982761 | 0.77 | SRC (0.53) | SRCAKT1 | |
| SCHEMBL7507622 | 0.72 | SRC (1.00) | SRCAKT1EGFRJAK3JAK2 | |
| SCHEMBL7509503 | 0.72 | SRC (1.00) | SRCEGFR | |
| SCHEMBL12070392 | 0.71 | SRC (0.70) | SRCEGFRLRRK2JAK3 | |
| SCHEMBL7512921 | 0.66 | SRC (1.00) | SRCEGFR | |
| SCHEMBL13063868 | 0.65 | SRC (0.74) | SRCAKT1 | |
| SCHEMBL14811476 | 0.63 | JAK3 (0.47) | SRCJAK3JAK2JAK1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137708-A1 | METHODS AND COMPOSITIONS FOR KINASE INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137708-A1 | METHODS AND COMPOSITIONS FOR KINASE INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137708-A1 | METHODS AND COMPOSITIONS FOR KINASE INHIBITION | SRC, ABL1, LCK | SRC 1/4885AKT1 145/4885EGFR 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.